Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer

Much effort has been dedicated to developing circulating tumor cells (CTC) as a noninvasive cancer biopsy, but with limited success as yet. In this study, we combine a method for isolation of highly pure CTCs using immunomagnetic enrichment/fluorescence-activated cell sorting with advanced whole gen...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer research (Chicago, Ill.) Jg. 77; H. 16; S. 4530
Hauptverfasser:	Gulbahce, Natali, Magbanua, Mark Jesus M, Chin, Robert, Agarwal, Misha R, Luo, Xuhao, Liu, Jia, Hayden, Daniel M, Mao, Qing, Ciotlos, Serban, Li, Zhenyu, Chen, Yanxiang, Chen, Xingpeng, Li, Yuxiang, Zhang, Rebecca Yu, Lee, Katharine, Tearle, Rick, Park, Emily, Drmanac, Snezana, Rugo, Hope S, Park, John W, Drmanac, Radoje, Peters, Brock A
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 15.08.2017
Schlagworte:	Female Genomics - methods Humans Middle Aged Neoplasm Metastasis Neoplasms - drug therapy Neoplastic Cells, Circulating - metabolism Neoplastic Cells, Circulating - pathology
ISSN:	1538-7445, 1538-7445
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	Much effort has been dedicated to developing circulating tumor cells (CTC) as a noninvasive cancer biopsy, but with limited success as yet. In this study, we combine a method for isolation of highly pure CTCs using immunomagnetic enrichment/fluorescence-activated cell sorting with advanced whole genome sequencing (WGS), based on long fragment read technology, to illustrate the utility of an accurate, comprehensive, phased, and quantitative genomic analysis platform for CTCs. Whole genomes of 34 CTCs from a patient with metastatic breast cancer were analyzed as 3,072 barcoded subgenomic compartments of long DNA. WGS resulted in a read coverage of 23× per cell and an ensemble call rate of >95%. These barcoded reads enabled accurate detection of somatic mutations present in as few as 12% of CTCs. We found in CTCs a total of 2,766 somatic single-nucleotide variants and 543 indels and multi-base substitutions, 23 of which altered amino acid sequences. Another 16,961 somatic single nucleotide variant and 8,408 indels and multi-base substitutions, 77 of which were nonsynonymous, were detected with varying degrees of prevalence across the 34 CTCs. On the basis of our whole genome data of mutations found in all CTCs, we identified driver mutations and the tissue of origin of these cells, suggesting personalized combination therapies beyond the scope of most gene panels. Taken together, our results show how advanced WGS of CTCs can lead to high-resolution analyses of cancers that can reliably guide personalized therapy. .
AbstractList	Much effort has been dedicated to developing circulating tumor cells (CTC) as a noninvasive cancer biopsy, but with limited success as yet. In this study, we combine a method for isolation of highly pure CTCs using immunomagnetic enrichment/fluorescence-activated cell sorting with advanced whole genome sequencing (WGS), based on long fragment read technology, to illustrate the utility of an accurate, comprehensive, phased, and quantitative genomic analysis platform for CTCs. Whole genomes of 34 CTCs from a patient with metastatic breast cancer were analyzed as 3,072 barcoded subgenomic compartments of long DNA. WGS resulted in a read coverage of 23× per cell and an ensemble call rate of >95%. These barcoded reads enabled accurate detection of somatic mutations present in as few as 12% of CTCs. We found in CTCs a total of 2,766 somatic single-nucleotide variants and 543 indels and multi-base substitutions, 23 of which altered amino acid sequences. Another 16,961 somatic single nucleotide variant and 8,408 indels and multi-base substitutions, 77 of which were nonsynonymous, were detected with varying degrees of prevalence across the 34 CTCs. On the basis of our whole genome data of mutations found in all CTCs, we identified driver mutations and the tissue of origin of these cells, suggesting personalized combination therapies beyond the scope of most gene panels. Taken together, our results show how advanced WGS of CTCs can lead to high-resolution analyses of cancers that can reliably guide personalized therapy. . Much effort has been dedicated to developing circulating tumor cells (CTC) as a noninvasive cancer biopsy, but with limited success as yet. In this study, we combine a method for isolation of highly pure CTCs using immunomagnetic enrichment/fluorescence-activated cell sorting with advanced whole genome sequencing (WGS), based on long fragment read technology, to illustrate the utility of an accurate, comprehensive, phased, and quantitative genomic analysis platform for CTCs. Whole genomes of 34 CTCs from a patient with metastatic breast cancer were analyzed as 3,072 barcoded subgenomic compartments of long DNA. WGS resulted in a read coverage of 23× per cell and an ensemble call rate of >95%. These barcoded reads enabled accurate detection of somatic mutations present in as few as 12% of CTCs. We found in CTCs a total of 2,766 somatic single-nucleotide variants and 543 indels and multi-base substitutions, 23 of which altered amino acid sequences. Another 16,961 somatic single nucleotide variant and 8,408 indels and multi-base substitutions, 77 of which were nonsynonymous, were detected with varying degrees of prevalence across the 34 CTCs. On the basis of our whole genome data of mutations found in all CTCs, we identified driver mutations and the tissue of origin of these cells, suggesting personalized combination therapies beyond the scope of most gene panels. Taken together, our results show how advanced WGS of CTCs can lead to high-resolution analyses of cancers that can reliably guide personalized therapy. Cancer Res; 77(16); 4530-41. ©2017 AACR.Much effort has been dedicated to developing circulating tumor cells (CTC) as a noninvasive cancer biopsy, but with limited success as yet. In this study, we combine a method for isolation of highly pure CTCs using immunomagnetic enrichment/fluorescence-activated cell sorting with advanced whole genome sequencing (WGS), based on long fragment read technology, to illustrate the utility of an accurate, comprehensive, phased, and quantitative genomic analysis platform for CTCs. Whole genomes of 34 CTCs from a patient with metastatic breast cancer were analyzed as 3,072 barcoded subgenomic compartments of long DNA. WGS resulted in a read coverage of 23× per cell and an ensemble call rate of >95%. These barcoded reads enabled accurate detection of somatic mutations present in as few as 12% of CTCs. We found in CTCs a total of 2,766 somatic single-nucleotide variants and 543 indels and multi-base substitutions, 23 of which altered amino acid sequences. Another 16,961 somatic single nucleotide variant and 8,408 indels and multi-base substitutions, 77 of which were nonsynonymous, were detected with varying degrees of prevalence across the 34 CTCs. On the basis of our whole genome data of mutations found in all CTCs, we identified driver mutations and the tissue of origin of these cells, suggesting personalized combination therapies beyond the scope of most gene panels. Taken together, our results show how advanced WGS of CTCs can lead to high-resolution analyses of cancers that can reliably guide personalized therapy. Cancer Res; 77(16); 4530-41. ©2017 AACR.
Author	Chin, Robert Hayden, Daniel M Chen, Xingpeng Rugo, Hope S Agarwal, Misha R Gulbahce, Natali Park, John W Tearle, Rick Luo, Xuhao Ciotlos, Serban Zhang, Rebecca Yu Chen, Yanxiang Li, Zhenyu Drmanac, Radoje Drmanac, Snezana Li, Yuxiang Lee, Katharine Mao, Qing Liu, Jia Magbanua, Mark Jesus M Peters, Brock A Park, Emily
Author_xml	– sequence: 1 givenname: Natali surname: Gulbahce fullname: Gulbahce, Natali organization: Complete Genomics, Inc, San Jose, California – sequence: 2 givenname: Mark Jesus M surname: Magbanua fullname: Magbanua, Mark Jesus M organization: Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California – sequence: 3 givenname: Robert surname: Chin fullname: Chin, Robert organization: Complete Genomics, Inc, San Jose, California – sequence: 4 givenname: Misha R surname: Agarwal fullname: Agarwal, Misha R organization: Complete Genomics, Inc, San Jose, California – sequence: 5 givenname: Xuhao surname: Luo fullname: Luo, Xuhao organization: Complete Genomics, Inc, San Jose, California – sequence: 6 givenname: Jia surname: Liu fullname: Liu, Jia organization: Complete Genomics, Inc, San Jose, California – sequence: 7 givenname: Daniel M surname: Hayden fullname: Hayden, Daniel M organization: Complete Genomics, Inc, San Jose, California – sequence: 8 givenname: Qing surname: Mao fullname: Mao, Qing organization: Complete Genomics, Inc, San Jose, California – sequence: 9 givenname: Serban surname: Ciotlos fullname: Ciotlos, Serban organization: Complete Genomics, Inc, San Jose, California – sequence: 10 givenname: Zhenyu surname: Li fullname: Li, Zhenyu organization: BGI-Shenzhen, Shenzhen, China – sequence: 11 givenname: Yanxiang surname: Chen fullname: Chen, Yanxiang organization: BGI-Shenzhen, Shenzhen, China – sequence: 12 givenname: Xingpeng surname: Chen fullname: Chen, Xingpeng organization: BGI-Shenzhen, Shenzhen, China – sequence: 13 givenname: Yuxiang surname: Li fullname: Li, Yuxiang organization: BGI-Shenzhen, Shenzhen, China – sequence: 14 givenname: Rebecca Yu surname: Zhang fullname: Zhang, Rebecca Yu organization: Complete Genomics, Inc, San Jose, California – sequence: 15 givenname: Katharine surname: Lee fullname: Lee, Katharine organization: Complete Genomics, Inc, San Jose, California – sequence: 16 givenname: Rick surname: Tearle fullname: Tearle, Rick organization: Complete Genomics, Inc, San Jose, California – sequence: 17 givenname: Emily surname: Park fullname: Park, Emily organization: Advanced Cell Diagnostics, Inc, Hayward, California – sequence: 18 givenname: Snezana surname: Drmanac fullname: Drmanac, Snezana organization: BGI-Shenzhen, Shenzhen, China – sequence: 19 givenname: Hope S surname: Rugo fullname: Rugo, Hope S organization: Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California – sequence: 20 givenname: John W surname: Park fullname: Park, John W organization: Division of Hematology/Oncology, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California – sequence: 21 givenname: Radoje surname: Drmanac fullname: Drmanac, Radoje email: bpeters@completegenomics.com, rdrmanac@completegenomics.com organization: BGI-Shenzhen, Shenzhen, China – sequence: 22 givenname: Brock A surname: Peters fullname: Peters, Brock A email: bpeters@completegenomics.com, rdrmanac@completegenomics.com organization: BGI-Shenzhen, Shenzhen, China
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/28811315$$D View this record in MEDLINE/PubMed
BookMark	eNpNkN9LwzAQx4NM3A_9E5Q8-tKZtE2WPI4ypzB_4cTHkqZXV2mTmbTCBP93M5wg93B38Lnv3X3HaGCsAYTOKZlSysQVIURELJ3F02x-H9FZRLgQR2hEWSKiWZqywb96iMbev4cRRgk7QcNYCEoTykbo-6lXpqs71dWfgF83tgG8BGNbwM_w0YPRtXnDtsJZ7XTfBCy06761DmfQNB4vjCoa8PgRnLdGNfUXlDizbVGbAFuD1xtwarvba9xBp_x-lcaZMhrcKTquVOPh7JAn6OV6sc5uotXD8jabryKdkqSLFC1lWSQyISlQzXUlNYmpVFwlsgoRF0UJgpeFSLnkQJmMCVcx01AQQoNHE3T5q7t1Njzlu7ytvQ73KwO29zmVsRSScykDenFA-6KFMt-6ulVul_9ZFv8AX-tybA
CitedBy_id	crossref_primary_10_1016_j_ccell_2025_07_008 crossref_primary_10_3390_ph15010075 crossref_primary_10_3892_ol_2019_10573 crossref_primary_10_1002_adma_201903663 crossref_primary_10_3390_diagnostics12040870 crossref_primary_10_1245_s10434_018_6540_4 crossref_primary_10_1158_1078_0432_CCR_17_2312 crossref_primary_10_3390_cells8080862 crossref_primary_10_1038_s41523_022_00445_7 crossref_primary_10_1016_j_bulcan_2017_10_021 crossref_primary_10_1158_0008_5472_CAN_17_2686 crossref_primary_10_3390_s18061762 crossref_primary_10_1038_s41568_019_0180_2 crossref_primary_10_3390_ijms18112423 crossref_primary_10_1080_14789450_2017_1392245 crossref_primary_10_1158_1078_0432_CCR_18_3888 crossref_primary_10_2147_BCTT_S388653 crossref_primary_10_1038_s41598_018_30047_y crossref_primary_10_3390_cancers11020143 crossref_primary_10_1016_j_jlb_2023_100135 crossref_primary_10_1038_s41523_018_0083_5 crossref_primary_10_1146_annurev_pharmtox_010818_021511 crossref_primary_10_1093_jnci_djaa113 crossref_primary_10_1016_j_ygeno_2022_110500 crossref_primary_10_1016_j_bbcan_2025_189336 crossref_primary_10_1002_advs_202414109 crossref_primary_10_1038_s41467_022_35296_0 crossref_primary_10_1089_dna_2017_3981 crossref_primary_10_3390_ijms21144826
ContentType	Journal Article
Copyright	2017 American Association for Cancer Research.
Copyright_xml	– notice: 2017 American Association for Cancer Research.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1158/0008-5472.CAN-17-0688
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1538-7445
ExternalDocumentID	28811315
Genre	Research Support, Non-U.S. Gov't Journal Article Case Reports
GroupedDBID	--- -ET 18M 29B 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAJMC ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AETEA AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 EBS ECM EIF EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO NPM OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 W2D W8F WH7 WOQ YKV YZZ 7X8 AAFWJ
ID	FETCH-LOGICAL-c403t-a1d9db39304e1c6cf9c0219a6a39f9f92bbde86db84696e159206a25ceb001472
IEDL.DBID	7X8
ISICitedReferencesCount	37
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000407613500029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1538-7445
IngestDate	Wed Oct 01 13:44:26 EDT 2025 Thu Apr 03 07:11:27 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	16
Language	English
License	2017 American Association for Cancer Research.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c403t-a1d9db39304e1c6cf9c0219a6a39f9f92bbde86db84696e159206a25ceb001472
Notes	ObjectType-Case Study-2 SourceType-Scholarly Journals-1 ObjectType-Feature-4 content type line 23 ObjectType-Report-1 ObjectType-Article-3
PMID	28811315
PQID	1929896699
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1929896699 pubmed_primary_28811315
PublicationCentury	2000
PublicationDate	2017-08-15
PublicationDateYYYYMMDD	2017-08-15
PublicationDate_xml	– month: 08 year: 2017 text: 2017-08-15 day: 15
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Cancer research (Chicago, Ill.)
PublicationTitleAlternate	Cancer Res
PublicationYear	2017
SSID	ssj0005105
Score	2.44258
Snippet	Much effort has been dedicated to developing circulating tumor cells (CTC) as a noninvasive cancer biopsy, but with limited success as yet. In this study, we...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	4530
SubjectTerms	Female Genomics - methods Humans Middle Aged Neoplasm Metastasis Neoplasms - drug therapy Neoplastic Cells, Circulating - metabolism Neoplastic Cells, Circulating - pathology
Title	Quantitative Whole Genome Sequencing of Circulating Tumor Cells Enables Personalized Combination Therapy of Metastatic Cancer
URI	https://www.ncbi.nlm.nih.gov/pubmed/28811315 https://www.proquest.com/docview/1929896699
Volume	77
WOSCitedRecordID	wos000407613500029&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Pa9swFBZbW8Yu3dqtXfYLFXpVZ1mSJZ1KMO12WEJKU5pbkPUDAq3dxskOhf7vfZIdctlhMAwCH2yM9PTeZ733vQ-hU8pCoavCEGd0TjhngWjFDKlsJmxmnPQmEYV_y_FYzWZ60h-4tX1Z5cYnJkftGhvPyH8AEtEKsLnW5w-PJKpGxexqL6HxGu0ygDLRquVs2y1cdCWMaVNLzkXP4KFCRQKDIoLL_KwcjgmVW_GVv6LMFG0u3_3vd75H-z3OxMPOMA7QK18fojejPpP-AT1frU2dCGbg7vBtVMnFP33d3Ht83VVXQ0zDTcDlYmmTxBfcTtf3zRKX_u6uxReJdNXiyQbNP3mHwbvAn3ZabDzt-hXEd4z8ykTm0sLiMlrZ8iO6ubyYlr9IL8VALM_YihjqtKuYZhn31BY2aAvgQJvCMB3gyqvKeVW4CuCMLjxgpDwrTC5skiaCaT5CO3VT-08IV4HyQDMmOJccBlVJGpwSjsvMGGcG6GQzsXMw9Zi_MLVv1u18O7UDdNytzvyh68kxz5WilFHx-R-e_oLe5jE4x8a24ivaDbDR_Te0Z_-sFu3ye7IhGMeT0QsfOtIy
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Quantitative+Whole+Genome+Sequencing+of+Circulating+Tumor+Cells+Enables+Personalized+Combination+Therapy+of+Metastatic+Cancer&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Gulbahce%2C+Natali&rft.au=Magbanua%2C+Mark+Jesus+M&rft.au=Chin%2C+Robert&rft.au=Agarwal%2C+Misha+R&rft.date=2017-08-15&rft.issn=1538-7445&rft.eissn=1538-7445&rft.volume=77&rft.issue=16&rft.spage=4530&rft_id=info:doi/10.1158%2F0008-5472.CAN-17-0688&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7445&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7445&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7445&client=summon